Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.
Fundación para la Investigación del Hospital Clínico de Valencian = 9226 May 2025 to 30 Jun 2026
Diabetes Mellitus Type 2
PepBank has 418 dulaglutide studies with results. 318 of them gave dulaglutide, with 1,919 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.
Searches 1,919 results and 718 papers. Newer studies from Europe PMC
Identifiers, parent molecule, targets and development stage, from curated data.
Dulaglutide contains two identical GLP-1 analog-linker-IgG4 Fc fusion chains. Each chain contains 275 residues. The marketed glycoprotein has an approximate mass of 63 kDa. It acts at GLP-1 receptors and is distinct from other GLP-1 agonists.
| Target | Action | Evidence |
|---|---|---|
| Glucagon-like peptide-1 receptorGLP1RP43220 (opens in a new tab) | Agonist | official prescribing informationSource (opens in a new tab) |
Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.
275 amino acids · 2 modifications · 2 disulfide bonds
Calculated from the two sequences. Curated notes are shown as given.
29 of 31 aligned residues identical (94%) · 2 substitutions · 244 added residues · GLP-1 (7-37) 7–37
Differences from the parent
Basis: The official label identifies the GLP-1(7-37) analog domain. Full-chain numbering includes a linker and an Fc domain.
Calculated from the two sequences with @pepdb/chem alignToParent (ungapped unless a gap scores higher). The record’s curated notes are shown as given.
No formula or molecular weight is listed for Dulaglutide (Trulicity).
Some values cannot be calculated. A modification changes this value and is not modeled here (for example a lipid, metal or linker).
@pepdb/chem 0.2.0 · EMBOSS pKa set · ExPASy residue masses
No charge curve
A modification changes this value and is not modeled here (for example a lipid, metal or linker).
275 residues. Each residue counts in one class; F and W count as aromatic.
Loads the 3D viewer (3Dmol.js, about 150 KB) and the model file from AlphaFold DB (EMBL-EBI).
An ideal alpha-helix projection. It shows where the hydrophobic residues fall if the peptide folds as a helix. It does not show that it does.
Eisenberg consensus (normalized) scale · + K, R · − D, E
Assumes an ideal α-helix: 100° per residue, 3.6 residues per turn. The arrow is the mean hydrophobic moment (Eisenberg et al. 1984) and points at the hydrophobic face.
| Position | Residue | Angle | Eisenberg consensus (normalized) |
|---|---|---|---|
| 1 | H | 0° | -0.40 |
| 2 | G | 100° | 0.48 |
| 3 | E | 200° | -0.74 |
| 4 | G | 300° | 0.48 |
| 5 | T | 40° | -0.05 |
| 6 | F | 140° | 1.19 |
| 7 | T | 240° | -0.05 |
| 8 | S | 340° | -0.18 |
| 9 | D | 80° | -0.90 |
| 10 | V | 180° | 1.08 |
| 11 | S | 280° | -0.18 |
| 12 | S | 20° | -0.18 |
| 13 | Y | 120° | 0.26 |
| 14 | L | 220° | 1.06 |
| 15 | E | 320° | -0.74 |
| 16 | E | 60° | -0.74 |
| 17 | Q | 160° | -0.85 |
| 18 | A | 260° | 0.62 |
| 19 | A | 0° | 0.62 |
| 20 | K | 100° | -1.50 |
| 21 | E | 200° | -0.74 |
| 22 | F | 300° | 1.19 |
| 23 | I | 40° | 1.38 |
| 24 | A | 140° | 0.62 |
| 25 | W | 240° | 0.81 |
| 26 | L | 340° | 1.06 |
| 27 | V | 80° | 1.08 |
| 28 | K | 180° | -1.50 |
| 29 | G | 280° | 0.48 |
| 30 | G | 20° | 0.48 |
| 31 | G | 120° | 0.48 |
| 32 | G | 220° | 0.48 |
| 33 | G | 320° | 0.48 |
| 34 | G | 60° | 0.48 |
| 35 | G | 160° | 0.48 |
| 36 | S | 260° | -0.18 |
| 37 | G | 0° | 0.48 |
| 38 | G | 100° | 0.48 |
| 39 | G | 200° | 0.48 |
| 40 | G | 300° | 0.48 |
| 41 | S | 40° | -0.18 |
| 42 | G | 140° | 0.48 |
| 43 | G | 240° | 0.48 |
| 44 | G | 340° | 0.48 |
| 45 | G | 80° | 0.48 |
| 46 | S | 180° | -0.18 |
| 47 | A | 280° | 0.62 |
| 48 | E | 20° | -0.74 |
| 49 | S | 120° | -0.18 |
| 50 | K | 220° | -1.50 |
| 51 | Y | 320° | 0.26 |
| 52 | G | 60° | 0.48 |
| 53 | P | 160° | 0.12 |
| 54 | P | 260° | 0.12 |
People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.
PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.
Counts are exact and come from studies that gave the peptide.
Studies by year
418 of 718 studies have results (58%), published 2010 to 2026. Top row: every study. Bottom row: studies with results about Dulaglutide (Trulicity), by class. The rows use different scales.
Studies718 in all, 2010 to 2026
Studies with results418 in all, 2010 to 2026
Retracted studies are left out. A study with results in two classes counts in both.
AI wrote and checked these results. AI can make mistakes, so check important results against the source.
Registered trials that test the peptide, with phase, status and dates. A dot marks trials with posted results.
124 trials match. Highest phase first. Data from ClinicalTrials.gov.
25 of 124 trials
A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes
NCT02750410Aug 2016 to 18 Jun 2018
Dulaglutide in Diabetic Patients, Relationship Between Arterial Stiffness, Endothelial Function, Clinical and Laboratory Variables
NCT038240021 Apr 2017 to 20 Apr 2018
A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes
NCT0331578028 Oct 2017 to 28 Feb 2018
Effect of Exenatide LAR or Dulaglutide on the Variability of 24-hour Heart Rate and Blood Pressure in Type 2 Diabetes
NCT0344414217 Nov 2017 to est. 30 Nov 2021
Metabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery Patients
NCT037430258 Mar 2019 to 2 May 2023
Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc
NCT041898483 Dec 2019 to 27 Feb 2020
GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response
NCT0438720115 May 2020 to 6 Oct 2023
Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes
NCT0489314826 May 2020 to est. 30 Dec 2022
25 trials · 3 ongoing · 1 not yet recruiting · 14 completed · 2 stopped early · 10 with posted results · source ClinicalTrials.gov (opens in a new tab)
Fundación para la Investigación del Hospital Clínico de Valencian = 9226 May 2025 to 30 Jun 2026
Diabetes Mellitus Type 2
The University of Hong Kongn = 37220 Mar 2024 to est. 31 Dec 2028
Myocardial Injury
First Affiliated Hospital of Wannan Medical Collegen = 468est. May 2026 to est. Jul 2027
T2DM (Type 2 Diabetes Mellitus) · CKD - Chronic Kidney Disease
MaryAnn Banerjin = 6021 Dec 2024 to est. 30 Jun 2028
Type 2 Diabetes (T2DM)
The Cleveland Clinicn = 6931 Jul 2024 to 20 May 2025
Diabetes Mellitus, Type 2 · Obesity · Gastroparesis
Eli Lilly and Companyn = 28230 Nov 2022 to 12 Aug 2024
Type 2 Diabetes
Eli Lilly and Companyn = 21229 Dec 2022 to 16 Jan 2024
Diabetes Mellitus, Type 2
Emory Universityn = 166 Aug 2021 to 22 Jun 2023
Hyperglycemia Stress
The University of Texas Health Science Center, Houstonn = 2315 May 2020 to 6 Oct 2023
Glucose Intolerance · Overweight and Obesity · Drug Effect · Adiposity
Elaine Chown = 9528 Jan 2022 to 30 Oct 2024
Diabetes Mellitus · Diabetic Kidney Disease
Emory Universityn = 288 Mar 2019 to 2 May 2023
Stress Hyperglycemia
Second Xiangya Hospital of Central South Universityn = 1201 May 2021 to est. 31 Dec 2023
Diabetes Mellitus, Type 2 · Overweight or Obesity
Novo Nordisk A/Sn = 1043 Dec 2019 to 27 Feb 2020
Healthy Volunteers · Diabetes Mellitus, Type 2 · Overweight · Obesity
Seoul National University Bundang Hospitaln = 135est. 1 Dec 2023 to est. 31 Dec 2025
Metabolic-associated Fatty Liver Disease · Type 2 Diabetes
Shanghai 10th People's Hospitaln = 6815 May 2021 to 10 May 2022
Polycystic Ovary Syndrome
Chungbuk National University Hospitaln = 4026 May 2020 to est. 30 Dec 2022
Type 2 Diabetes Mellitus · Glucose, High Blood
Eli Lilly and Companyn = 31218 Oct 2018 to 12 Apr 2019
Diabetes Mellitus, Type 2
University of Guadalajaran = 3017 Nov 2017 to est. 30 Nov 2021
Diabetes Mellitus, Type 2
Eli Lilly and Companyn = 159Aug 2016 to 18 Jun 2018
Type 2 Diabetes
Eli Lilly and Companyn = 1228 Oct 2017 to 28 Feb 2018
Type 2 Diabetes
Central Hospital, Nancy, Francen = 93est. 1 Sept 2019 to est. 30 Mar 2024
Diabetes Mellitus, Type 2 · NASH - Nonalcoholic Steatohepatitis
University of Palermon = 921 Apr 2017 to 20 Apr 2018
Diabetes Mellitus
Eli Lilly and Companyn = 1708 Jul 2026 to est. Mar 2030
Diabetes Mellitus, Type 2
Zagazig Universityn = 15014 Nov 2025 to 21 Apr 2026
Non-diabetec Obesity · Obesity (Disorder)
Zagazig Universityn = 15918 Oct 2025 to 17 Mar 2026
Obese Diabetics · Obese Non Diabetic
19 more mention it but do not test it. They are not trials of Dulaglutide (Trulicity): they only measure it (a blood level or an eligibility term) or name it in their text.
Studies on this peptide. Some have results. The others have none yet.
718 studies match. Retracted studies are left out.
Showing 22 of 718 studiesquery qry_de030d0e2797f102cf97332f
418 studies in all, 12 on this page
Randomized controlled trial · 2019
Gerstein et al. 2019Lancet (London, England)n = 9,901cited by 2,264
PMID 31189511DOI 10.1016/s0140-6736(19)31149-3PUB-31189511
Randomized controlled trial · 2018
Frias et al. 2018Lancet (London, England)cited by 651
PMID 30293770DOI 10.1016/s0140-6736(18)32260-8PUB-30293770
Randomized controlled trial · 2018
Pratley et al. 2018The lancet. Diabetes & endocrinologyn = 598cited by 614
PMID 29397376DOI 10.1016/s2213-8587(18)30024-xPUB-29397376
Randomized controlled trial · 2018
Tuttle et al. 2018The lancet. Diabetes & endocrinologyn = 192cited by 506
PMID 29910024DOI 10.1016/s2213-8587(18)30104-9PUB-29910024
Randomized controlled trial · 2019
Gerstein et al. 2019Lancet (London, England)n = 9,901cited by 467
PMID 31189509DOI 10.1016/s0140-6736(19)31150-xPUB-31189509
Randomized controlled trial · 2023
Rosenstock et al. 2023Lancet (London, England)n = 71cited by 309
PMID 37385280DOI 10.1016/s0140-6736(23)01053-xPUB-37385280
Other design · 2020
Hartman et al. 2020Diabetes carecited by 283
PMID 32291277PMC7245348DOI 10.2337/dc19-1892PUB-32291277
Randomized controlled trial · 2014
Umpierrez et al. 2014Diabetes carecited by 272
PMID 24842985DOI 10.2337/dc13-2759PUB-24842985
Animal study (in vivo) · monkey, mouse and rat · 2010
Glaesner et al. 2010Diabetes/metabolism research and reviewscited by 233
PMID 20503261DOI 10.1002/dmrr.1080PUB-20503261
Randomized controlled trial · 2015
Giorgino et al. 2015Diabetes carecited by 203
PMID 26089386DOI 10.2337/dc14-1625PUB-26089386
Randomized controlled trial · 2020
Kuchay et al. 2020Diabetologian = 52cited by 201
PMID 32865597DOI 10.1007/s00125-020-05265-7PUB-32865597
Randomized controlled trial · 2015
Blonde et al. 2015Lancet (London, England)n = 295cited by 185
PMID 26009229DOI 10.1016/s0140-6736(15)60936-9PUB-26009229
229 studies in all, 10 on this page
PubMed tag: review-article, Review · 2021
Nauck et al. 2021Molecular metabolismcited by 1,202
PMID 33068776PMC8085572DOI 10.1016/j.molmet.2020.101102PUB-33068776
PubMed tag: Randomized Controlled Trial, Clinical Trial, Phase III · 2014
Dungan et al. 2014Lancet (London, England)cited by 386
PMID 25018121DOI 10.1016/s0140-6736(14)60976-4PUB-25018121
PubMed tag: Randomized Controlled Trial · 2014
Wysham et al. 2014Diabetes carecited by 313
PMID 24879836DOI 10.2337/dc13-2760PUB-24879836
PubMed tag: none · 2017
Hinnen et al. 2017Diabetes spectrum : a publication of the American Diabetes Associationcited by 293
PMID 28848315PMC5556578DOI 10.2337/ds16-0026PUB-28848315
PubMed tag: Randomized Controlled Trial, Multicenter Study · 2020
Cukierman-Yaffe et al. 2020The Lancet. Neurologycited by 242
PMID 32562683DOI 10.1016/s1474-4422(20)30173-3PUB-32562683
PubMed tag: Randomized Controlled Trial · 2014
Nauck et al. 2014Diabetes carecited by 227
PMID 24742660PMC4113177DOI 10.2337/dc13-2761PUB-24742660
PubMed tag: review-article, Review · 2021
Mantovani et al. 2021Metabolitescited by 226
PMID 33513761PMC7911747DOI 10.3390/metabo11020073PUB-33513761
PubMed tag: Randomized Controlled Trial, Clinical Trial, Phase III · 2018
Ludvik et al. 2018The lancet. Diabetes & endocrinologycited by 205
PMID 29483060DOI 10.1016/s2213-8587(18)30023-8PUB-29483060
PubMed tag: Review · 2019
Nauck et al. 2019European journal of endocrinologycited by 188
PMID 31600725DOI 10.1530/eje-19-0566PUB-31600725
PubMed tag: Review · 2019
Gentilella et al. 2019Diabetes/metabolism research and reviewscited by 185
PMID 30156747DOI 10.1002/dmrr.3070PUB-30156747
These studies name Dulaglutide (Trulicity) but give no result for it (for example, the results concern another peptide in the study).
PubMed tag: Randomized Controlled Trial, Clinical Trial, Phase I · 2018
Coskun et al. 2018Molecular metabolismcited by 700
PMID 30473097PMC6308032DOI 10.1016/j.molmet.2018.09.009PUB-30473097
PubMed tag: Clinical Trial Protocol · 2024
Nicholls et al. 2024American heart journalcited by 197
PMID 37758044DOI 10.1016/j.ahj.2023.09.007PUB-37758044
PubMed tag: Meta-Analysis · 2017
Monami et al. 2017Diabetes, obesity & metabolismcited by 189
PMID 28244632DOI 10.1111/dom.12926PUB-28244632
Page 1 of 9
Nicholls SJ · The New England journal of medicine · 2025
Randomized controlled trial · 6 results
Nissen SE · JAMA cardiology · 2026
Randomized controlled trial · 10 results
Gerstein HC · Lancet (London, England) · 2019
Randomized controlled trial · 3 results
Ferrannini G · European heart journal · 2021
Randomized controlled trial · 4 results
Konig M · Journal of the Endocrine Society · 2020
Randomized controlled trial · 7 results
Frias J · Journal of the Endocrine Society · 2020
Randomized controlled trial · 31 results
Wang W · Diabetes, obesity & metabolism · 2019
Randomized controlled trial · 9 results
Chen YH · Diabetes, obesity & metabolism · 2018
Randomized controlled trial · 11 results
Li Y · Diabetes therapy : research, treatment and education of diabetes and related disorders · 2019
Randomized controlled trial · 7 results
Pratley RE · The lancet. Diabetes & endocrinology · 2018
Randomized controlled trial · 21 results
Morioka T · Diabetes, obesity & metabolism · 2024
Randomized controlled trial · 9 results
Liu L · Journal of diabetes · 2025
Randomized controlled trial · 19 results
He Y · The lancet. Diabetes & endocrinology · 2025
Randomized controlled trial · 5 results
Shi LX · Journal of diabetes investigation · 2020
Randomized controlled trial · 15 results
Araki E · Diabetes, obesity & metabolism · 2015
Randomized controlled trial · 5 results
Pozzilli P · Diabetes, obesity & metabolism · 2017
Randomized controlled trial · 8 results
Blonde L · Lancet (London, England) · 2015
Randomized controlled trial · 9 results
Wang W · Diabetes, obesity & metabolism · 2023
Randomized controlled trial · 9 results
Billings LK · Annals of internal medicine · 2025
Randomized controlled trial · 8 results
Lengsfeld S · EClinicalMedicine · 2023
Randomized controlled trial · 5 results
Lüthi H · EClinicalMedicine · 2024
Randomized controlled trial · 9 results
Journal of the Endocrine Society · 2022
Randomized controlled trial · 4 results
Tuttle KR · The lancet. Diabetes & endocrinology · 2018
Randomized controlled trial · 17 results
Arslanian SA · The New England journal of medicine · 2022
Randomized controlled trial · 7 results
Jendle J · Diabetes, obesity & metabolism · 2016
Randomized controlled trial · 10 results
Kimura T · Diabetes, obesity & metabolism · 2023
Randomized controlled trial · 21 results
Zhang B · Diabetes care · 2024
Randomized controlled trial · 15 results
Zhang Q · Expert opinion on biological therapy · 2023
Randomized controlled trial · 6 results
Adly AAM · Diabetologia · 2026
Randomized controlled trial · 10 results
Rosenstock J · Lancet (London, England) · 2023
Randomized controlled trial · 31 results
Zhang Y · Nutrients · 2023
Randomized controlled trial · 9 results
Gao X · Clinical and translational science · 2024
Randomized controlled trial · 8 results
Yabe D · The lancet. Diabetes & endocrinology · 2020
Randomized controlled trial · 28 results
Takahashi Y · Diabetes, obesity & metabolism · 2023
Randomized controlled trial · 9 results
Kuchay MS · Diabetologia · 2020
Randomized controlled trial · 7 results
Kondo Y · Diabetology international · 2024
Randomized controlled trial · 5 results
Omachi T · Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024
Randomized controlled trial · 10 results
Winzeler B · The Journal of clinical investigation · 2021
Randomized controlled trial · 4 results
Winzeler B · Journal of the Endocrine Society · 2021
Randomized controlled trial · 4 results
Šiarnik P · Neurology and therapy · 2026
Randomized controlled trial · 12 results
Jun JE · Frontiers in endocrinology · 2026
Randomized controlled trial · 9 results
Nagaike H · Diabetes therapy : research, treatment and education of diabetes and related disorders · 2019
Randomized controlled trial · 15 results
Winzeler B · Endocrine · 2020
Randomized controlled trial · 5 results
de la Peña A · Diabetes, obesity & metabolism · 2017
Randomized controlled trial · 11 results
Inoue M · Diabetes therapy : research, treatment and education of diabetes and related disorders · 2019
Randomized controlled trial · 7 results
Frias JP · Lancet (London, England) · 2018
Randomized controlled trial · 33 results
Umpierrez G · Diabetes care · 2014
Randomized controlled trial · 10 results
Giorgino F · Diabetes care · 2015
Randomized controlled trial · 11 results
Frias JP · Diabetes care · 2021
Randomized controlled trial · 12 results
Weinstock RS · Diabetes, obesity & metabolism · 2015
Randomized controlled trial · 14 results
Approval and sport status, and the safety outcomes reported in study results. Laws and labels change, so check the regulator for the current status.
| Jurisdiction | Body | Status | As of | Source |
|---|---|---|---|---|
| US | FDA |
| 21 Oct 2026 | dailymed.nlm.nih.gov (opens in a new tab) |
| EU | EMA |
| 21 Oct 2026 | ema.europa.eu (opens in a new tab) |
| Sport | WADA | Not listed as banned by WADA This check does not establish individual athlete eligibility. | 2026 List | wada-ama.org (opens in a new tab) |
488 safety results for Dulaglutide (Trulicity).
In patients with diabetes and cardiovascular disease, gastrointestinal adverse events were less common with dulaglutide than tirzepatide.
Randomized controlled trialn = 13,165
1 more measurement in the study.
In participants with diabetes and atherosclerotic cardiovascular disease, nausea was less common with dulaglutide than tirzepatide.
Randomized controlled trialn = 13,165
In T2D patients with cardiovascular disease or risk factors, all-cause mortality did not differ significantly between dulaglutide and placebo.
Randomized controlled trialn = 9,901
2 more measurements in the study.
In REWIND patients aged ≥65 years, composite safety incidence was 15.2% with dulaglutide versus 16.1% with placebo.
Randomized controlled trialn = 5,256
In patients with T2D, adverse-event discontinuation was similar with dulaglutide 3 mg and 1.5 mg.
Randomized controlled trialn = 1,228
In mainly Asian patients with T2DM, total hypoglycemia incidence was lower with dulaglutide than glargine.
Randomized controlled trialn = 774
In East-Asian patients with T2D, dulaglutide had lower total hypoglycaemia rates than glimepiride.
Randomized controlled trialn = 737
In Chinese T2DM patients, total hypoglycemia rates were lower with dulaglutide than glargine.
Randomized controlled trialn = 607
The top 24 of 445 results.
The doses that these studies used. They are not recommendations.
1.5 mg weeklyHuman
1.5 mg weeklyHuman
1.5 mg weeklyHuman
1.5 mg weeklyHuman
1.5 mg once weeklyHuman
1.5 mg once weeklyHuman
6 of 260 shown
PepBank is a research reference. Talk to a doctor before you use any peptide.
Data version, change history and code for this peptide.
curl -s https:// pepbank.io/ v1/ briefs/ dulaglutideEvidence summary for Dulaglutide (Trulicity): counts by class, key results with sources, notices, data version.
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Top outcomes
The 8 outcome groups with the most study results, by evidence class.
Data version 308560. Bar length is the number of results, not the size of an effect.
Evidence matrix
Study results by outcome and evidence class. Arrows show how the measured outcome moved, not whether the change is good.
| Outcome group | Human | Animal | Lab | Computer model | Total |
|---|---|---|---|---|---|
| Glycemic controlMetabolic and weight | Human: 537 results from 151 studies: 124 increase, 310 decrease, 57 no significant change, 1 mixed, 45 not reported. Strongest design: Randomized controlled trial | Animal: 26 results from 14 studies: 7 increase, 8 decrease, 2 no significant change, 2 mixed, 7 not reported. Strongest design: Animal study (in vivo) | Lab: 1 result from 1 study: 1 not reported. Strongest design: Ex vivo tissue | No results | 564 |
| Adverse eventsWhole body | Human: 235 results from 103 studies: 21 increase, 31 decrease, 47 no significant change, 136 not reported. Strongest design: Randomized controlled trial | Animal: 43 results from 8 studies: 12 increase, 1 decrease, 22 no significant change, 8 not reported. Strongest design: Animal study (in vivo) | No results | No results | 278 |
| Gastrointestinal adverse eventsGastrointestinal | Human: 179 results from 66 studies: 34 increase, 13 decrease, 16 no significant change, 116 not reported. Strongest design: Randomized controlled trial | No results | No results | No results | 179 |
| Body weightMusculoskeletal | Human: 172 results from 97 studies: 31 increase, 110 decrease, 22 no significant change, 1 mixed, 8 not reported. Strongest design: Randomized controlled trial | Animal: 6 results from 5 studies: 6 decrease. Strongest design: Animal study (in vivo) | No results | No results | 178 |
| Kidney functionKidney and urinary | Human: 56 results from 17 studies: 14 increase, 25 decrease, 13 no significant change, 1 mixed, 3 not reported. Strongest design: Randomized controlled trial | Animal: 7 results from 3 studies: 6 decrease, 1 not reported. Strongest design: Animal study (in vivo) | No results | No results | 63 |
| PharmacokineticsPharmacology | Human: 40 results from 8 studies: 3 increase, 4 decrease, 6 no significant change, 1 mixed, 26 not reported. Strongest design: Randomized controlled trial | Animal: 4 results from 3 studies: 1 decrease, 1 mixed, 2 not reported. Strongest design: Animal study (in vivo) | No results | No results | 44 |
| Cardiovascular eventsCardiovascular | Human: 40 results from 18 studies: 12 increase, 11 decrease, 15 no significant change, 2 not reported. Strongest design: Randomized controlled trial | No results | No results | No results | 40 |
| LipidsMetabolic and weight | Human: 35 results from 17 studies: 7 increase, 16 decrease, 5 no significant change, 1 mixed, 6 not reported. Strongest design: Randomized controlled trial | Animal: 2 results from 2 studies: 2 decrease. Strongest design: Animal study (in vivo) | No results | No results | 37 |
| Treatment adherence and retentionWhole body | Human: 30 results from 10 studies: 12 increase, 5 decrease, 1 no significant change, 12 not reported. Strongest design: Randomized controlled trial | No results | No results | No results | 30 |
| MortalityWhole body | Human: 23 results from 17 studies: 8 increase, 1 decrease, 4 no significant change, 10 not reported. Strongest design: Randomized controlled trial | No results | No results | No results | 23 |
| Inflammation markersRespiratory | Human: 22 results from 7 studies: 4 increase, 14 decrease, 3 no significant change, 1 not reported. Strongest design: Randomized controlled trial | Animal: 45 results from 10 studies: 43 decrease, 2 no significant change. Strongest design: Animal study (in vivo) | Lab: 1 result from 1 study: 1 decrease. Strongest design: In vitro (cells) | No results | 68 |
| Healthcare costs and utilizationWhole body | Human: 22 results from 5 studies: 1 increase, 16 decrease, 4 no significant change, 1 not reported. Strongest design: Randomized controlled trial | No results | No results | No results | 22 |
12 outcome groups shown of 58 · 1,919 study results
Data version 308560. Shade grows with the number of results. Every cell shows the exact count.
Trials by phase
25 registered trials loaded of 124, grouped by phase and shown by status.
Source: ClinicalTrials.gov, data version 308560. Status is the registry status. The counts cover only the loaded trials.